Skip to content

Synergism of dendritic cell vaccination and anti-PD-L1 immune check-point blockade to sensitize recurrent glioblastoma to anti-tumoral immunity

Status
Withdrawn
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-525397-19-00
Enrollment
6
Registered
2026-08-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Glioblastoma

Brief summary

Immunological responsiveness of blood T cells as determined by interferon-gamma and multi-cytokine responses towards tumor lysate-loaded DC during vaccination.

Detailed description

Feasibility (production and application of therapeutics)., Safety based on the frequency and severity of AE with toxicity graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)., Survival based on overall and progression-free survival (according to modified Response Assessment in Neuro-Oncology (RANO) criteria) at six months after surgery.

Interventions

Sponsors

Heinrich-Heine-Universitaet Duesseldorf
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Immunological responsiveness of blood T cells as determined by interferon-gamma and multi-cytokine responses towards tumor lysate-loaded DC during vaccination.

Secondary

MeasureTime frame
Feasibility (production and application of therapeutics)., Safety based on the frequency and severity of AE with toxicity graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)., Survival based on overall and progression-free survival (according to modified Response Assessment in Neuro-Oncology (RANO) criteria) at six months after surgery.

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 21, 2026